These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 32192503)

  • 61. Sodium-glucose transporter 2 inhibitors for renal and cardiovascular protection in US adults with type 2 diabetes: Impact of the 2020 KDIGO clinical practice guidelines.
    Ciardullo S; Trevisan R; Perseghin G
    Pharmacol Res; 2021 Apr; 166():105530. PubMed ID: 33675963
    [TBL] [Abstract][Full Text] [Related]  

  • 62. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Furtado RHM; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Lancet; 2019 Jan; 393(10166):31-39. PubMed ID: 30424892
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The landscape of diabetic kidney disease transformed.
    Tuttle KR
    Nat Rev Nephrol; 2020 Feb; 16(2):67-68. PubMed ID: 31831876
    [No Abstract]   [Full Text] [Related]  

  • 64. SGLT-2 inhibitors in diabetes: a focus on renoprotection.
    Gonzalez DE; Foresto RD; Ribeiro AB
    Rev Assoc Med Bras (1992); 2020 Jan; 66Suppl 1(Suppl 1):s17-s24. PubMed ID: 31939531
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?
    Flores E; Santos-Gallego CG; Diaz-Mejía N; Badimon JJ
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):213-222. PubMed ID: 29679303
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Antidiabetic SGLT-2 inhibitors prevent progression of chronic kidney disease].
    Heine GH
    Dtsch Med Wochenschr; 2020 Jun; 145(11):762-766. PubMed ID: 32492746
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Clinical potential of canagliflozin in cardiovascular risk reduction in patients with type 2 diabetes.
    Skelley JW; Carter BS; Roberts MZ
    Vasc Health Risk Manag; 2018; 14():419-428. PubMed ID: 30573964
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Sodium-glucose Cotransporter 2 Inhibitors: Potential Cardiovascular and Mortality Benefits.
    Lovic D; Pittaras A; Kallistratos M; Tsioufis C; Grassos C; Djordjevic D; Tasic I; Manolis A
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):114-119. PubMed ID: 29485012
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Use of SGLT-2 Inhibitors in Patients with Chronic Kidney Disease.
    Mottl A
    J Fam Pract; 2021 Jul; 70(6S):S59-S64. PubMed ID: 34432626
    [TBL] [Abstract][Full Text] [Related]  

  • 70. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Prevention of Heart Failure in Patients with Diabetes: Role of Diabetes Medications.
    Bassi N; Fonarow GC
    Curr Cardiol Rep; 2018 Sep; 20(11):112. PubMed ID: 30259198
    [TBL] [Abstract][Full Text] [Related]  

  • 72. How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study.
    Birkeland KI; Bodegard J; Norhammar A; Kuiper JG; Georgiado E; Beekman-Hendriks WL; Thuresson M; Pignot M; Herings RMC; Kooy A
    Diabetes Obes Metab; 2019 Apr; 21(4):968-974. PubMed ID: 30537226
    [TBL] [Abstract][Full Text] [Related]  

  • 73. SGLT-2 inhibitors as cardio-renal protective agents.
    Caruso I; Giorgino F
    Metabolism; 2022 Feb; 127():154937. PubMed ID: 34808144
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Statin use in patients with diabetes and kidney disease: the Japanese experience.
    Koya D; Campese VM
    J Atheroscler Thromb; 2013; 20(5):407-24. PubMed ID: 23518468
    [TBL] [Abstract][Full Text] [Related]  

  • 75. GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis.
    Grenet G; Ribault S; Nguyen GB; Glais F; Metge A; Linet T; Kassai-Koupai B; Cornu C; Bejan-Angoulvant T; Erpeldinger S; Boussageon R; Gouraud A; Bonnet F; Cucherat M; Moulin P; Gueyffier F
    PLoS One; 2019; 14(6):e0217701. PubMed ID: 31237921
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Advancing American Kidney Health and the Role of Sodium-Glucose Cotransporter-2 Inhibitors: A Missed Opportunity.
    Li J; Tummalapalli SL; Mendu ML
    Clin J Am Soc Nephrol; 2021 Oct; 16(10):1584-1586. PubMed ID: 34135024
    [No Abstract]   [Full Text] [Related]  

  • 77. Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes.
    Kramer CK; Zinman B
    Annu Rev Med; 2019 Jan; 70():323-334. PubMed ID: 30256723
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus.
    Carbone S; Dixon DL
    Cardiovasc Diabetol; 2019 May; 18(1):64. PubMed ID: 31138195
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [The mechanisms and clinical potential: sodium-glucose cotransporter 2 (SGLT-2) inhibitors treating diabetic kidney disease].
    Wang YJ; Hao CM
    Sheng Li Xue Bao; 2018 Dec; 70(6):663-669. PubMed ID: 30560277
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials.
    Giugliano D; Maiorino MI; Longo M; Bellastella G; Chiodini P; Esposito K
    Endocrine; 2019 Jul; 65(1):15-24. PubMed ID: 31028667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.